Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05790941
NCT05790941RecruitingEarly Phase 1

Proof of Concept of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation for Eyebrows

Aneira Pharma, Inc.2 sites in 1 country12 target enrollmentStarted: March 11, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Early Phase 1
Status
Recruiting
Enrollment
12
Locations
2
Primary Endpoint
Target Area Hair Count
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.

Detailed Description

A Single-Blind placebo controlled trial of the efficacy and safety of the treatment of hypotrichosis of the eyebrows comparing a subset of patients receiving a combination of latanoprost/minoxidil formulation as compared to placebo measured by a validated imaging system.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
Single (Participant)

Masking Description

Unlabeled bottle.

Eligibility Criteria

Ages
22 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Subjects, age 22 to 65 years, in general good health.
  • •Patients with diagnosed hypotrichosis of the eyebrows.
  • •Subjects with active hair loss within the last 12 months.
  • •Patients willing to refrain from initiation of any new vitamins or nutritional supplements for the duration of the study.
  • •Patients willing to refrain from use of any hair growth therapies (oral or topical) other than the investigational product.

Exclusion Criteria

  • •Subjects with an active disease or infection, or chronic dermatological condition (eczema, psoriasis, infection, etc.) of the scalp that may interfere with the assessment of scalp skin health in the treated regions.
  • •History of hair transplants, scalp reduction, current hair weave or tattooing in the target area, artificial hair coloring two months prior to initiation of study which makes it difficult to perform hair count assessment.
  • •Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a time period.
  • •Subjects with a history of chemotherapy, receiving cytotoxic agents, radiation, or laser/surgical therapy of the scalp within the past 12 months.
  • •Any known or underlying medical problem that could influence hair growth such as HIV infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator.
  • •Subjects with clinical diagnosis of hair loss other than hypotrichosis of the eyebrows.
  • •Subjects with severe cardiovascular disease, uncontrolled or untreated hypertension, arrythmia or clinically relevant hypotension.
  • •Subjects with known or suspected hypersensitivity or allergic reaction to any of the active or inactive components of the test articles.
  • •Pregnant or lactating females or planning to become pregnant for the duration of the study.
  • •Subjects using medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.
  • •Current enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation.
  • •Current or recent (2 months) history of severe diet or eating disorder.

Outcomes

Primary Outcomes

Target Area Hair Count

Time Frame: 90 days

Target Area Hair Count as Determined by the Brigham Tool for Alopecia

Secondary Outcomes

  • Standardized Global Photographs(90 days)
  • Change in Total Area Hair Darkness(90 days)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Unknown
Phase 2
Latanoprost for the Treatment of Menière's DiseaseMenière's Disease
NCT01973114Synphora AB100
Completed
Phase 3
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair LossAndrogenetic Alopecia
NCT00151515Johnson & Johnson Consumer and Personal Products Worldwide352
Recruiting
Early Phase 1
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast CancerAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Endocrine Therapy-Induced AlopeciaPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8
NCT05417308Ohio State University Comprehensive Cancer Center50
Completed
Phase 2
Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X SyndromeFragile X Syndrome
NCT02680379Université de Sherbrooke22
Completed
Phase 4
Efficacy and Tolerability of an Innovative Formulation of BAK-free LatanoprostPrimary Open-angle Glaucoma
NCT03331770Laboratorios Poen103